(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2015 (30.12.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/199356 A1

(51) **International Patent Classification**:
A61K 9/16 (2006.01) *A61K 9/24* (2006.01)
A61K 9/48 (2006.01) *A61K 9/20* (2006.01)

(21) **International Application Number**:
PCT/KR2015/005779

(22) **International Filing Date**:
9 June 2015 (09.06.2015)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
10-2014-0078388 25 June 2014 (25.06.2014) KR

(71) **Applicant**: **HANMI PHARM. CO., LTD.** [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-958 (KR).

(72) **Inventors**: **KIM, Yong Il**; 732-504, 52, Jeongja-ro 42beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 440-730 (KR). **JEONG, Ha Young**; 111-809, 119, Dongjak-daero 29-gil, Dongjak-gu, Seoul 156-772 (KR). **KIM, Kyeong Soo**; 116-1901, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). **LEE, Seung Jun**; 216-1902, 299, Sanbon-ro, Gunpo-si, Gyeonggi-do 435-765 (KR). **PARK, Jae Hyun**; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-737 (KR). **WOO, Jong Soo**; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR).

(74) **Agent**: **Y.P.LEE, MOCK & PARTNERS**; 12F Daelim Acrotel, 13 Eonju-ro 30-gil, Gangnam-gu, Seoul 135-971 (KR).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/199356 A1

(54) **Title**: COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN AND A PROCESS FOR THE PREPARATION THEREOF

(57) **Abstract**: Provided is a solid composite formulation for oral administration that includes: an ezetimibe-wet granule portion including ezetimibe that is wet-granulated using a fluid-bed granulator; and a rosuvastatin mixture portion including rosuvastatin or a pharmaceutically acceptable salt thereof.